HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease: Trial design, recruitment, and baseline characteristics

American Heart Journal · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles